Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.
Cancer Discovery|August 20, 2013
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphomaThomas Clozel, ShaoNing Yang, Rebecca L Elstrom, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 2021
Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic HealthSabrina E Racine-Brzostek, He S Yang, Gwendolyne A Jack, et al.
Blood Cancer Journal|April 22, 2026
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein responseMikhail Roshal, Isabella Y Kong, Wikum Dinalankara, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Single-cell spatial mapping reveals dynamic bone marrow microarchitectural alterations and enhances clinical diagnostics in MDSRyan Nachman, Aleksandra Kopacz, Caitlin Unkenholz, et al.
Cancer Cell|March 8, 2024
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesisDarko Barisic, Christopher R Chin, Cem Meydan, et al.
Leukemia|July 1, 2026
Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasmsRyan Nachman, Aleksandra Kopacz, Caitlin Unkenholz, et al.
Cancer Cell|December 6, 2024
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell functionYusuke Isshiki, Xi Chen, Matt Teater, et al.
Nature Communications|April 3, 2024
Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironmentJie Li, Christopher R Chin, Hsia-Yuan Ying, et al.
Cancer Cell|March 8, 2024
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisionsQing Deng, Priya Lakra, Panhong Gou, et al.
Pageof 18